The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Drugs 52

Drugs Genotype Bioavailability Medicine 52

The Pharma Data

MARCH 16, 2022

TIB Molbiol offers a broad range of VirSNiP variant test kits for the detection of key spike protein mutations. The company launched eight RUO VirSNiP test kits for use on LightCycler® and cobas z 480 analyzers, for the detection of key spike protein mutations present in the novel B.1.1.529 1.1.529 Omicron SARS-CoV-2 variant.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Drug Discovery World

DECEMBER 12, 2023

Context and treatment potential AATD is an inherited, autosomal recessive genetic disorder that is most frequently caused by a single nucleotide variant (SNV) mutation in the SERPINA1 gene, the most common of which is the ‘PiZ’ mutation.

RNA 52

RNA In-Vivo Genotype Genetics 52

XTalks

DECEMBER 12, 2023

Efficacy: By comparing with baseline data, clinicians can discern changes in key imaging biomarkers, from the size of brain structures like grey matter, white matter and CSF, to the size of an infarct or the presence of specific proteins like tau or amyloid.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

Roots Analysis

AUGUST 31, 2023

Recent advances in DNA sequencing technologies have led to significant developments in healthcare-focused research on precision medicine and diagnostics. In this context, nutrigenomics studies have demonstrated that individuals who have genetic risk alleles for obesity can hasten the weight loss with the help of some dietary modifications.

Genome 40

Genome Genomics Genetics Gene 40

The Pharma Data

NOVEMBER 24, 2020

PH1 is an ultra-rare genetic disease characterized by oxalate overproduction. Oxlumo marks our third FDA approval in less than three years, positioning us to meet or exceed our Alnylam 2020 strategy and goals, and further highlighting the productivity of our RNAi platform and the speed at which we can bring innovative medicines to patients.

FDA Approval 52

FDA Approval Production RNA Medicine 52